Top

Published in:

Open Access 01-09-2010

A Re-evaluation of the “Oncogenic” Nature of Wnt/β-catenin Signaling in Melanoma and Other Cancers

Authors: Olivia M. Lucero, David W. Dawson, Randall T. Moon, Andy J. Chien

Published in: Current Oncology Reports | Issue 5/2010

Abstract

In cancer, Wnt/β-catenin signaling is ubiquitously referred to as an “oncogenic” pathway that promotes tumor progression. This review examines how the regulation and downstream effects of Wnt/β-catenin signaling in cancer varies depending on cellular context, with a focus on malignant melanoma. We emphasize that the cellular homeostasis of Wnt/β-catenin signaling may represent a more appropriate concept than the simplified view of the Wnt/β-catenin pathway as either oncogenic or tumor-suppressing. Ultimately, a more refined understanding of the contextual regulation of Wnt/β-catenin signaling will be essential for addressing if and how therapeutic targeting of this pathway could be leveraged for patient benefit.

Chien AJ, Conrad WH, Moon RT: A Wnt survival guide: from flies to human disease. J Invest Dermatol 2009, 129:1614–1627.CrossRefPubMed

Torres MA, Yang-Snyder JA, Purcell SM, et al.: Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. J Cell Biol 1996, 133:1123–1137.CrossRefPubMed

Stoick-Cooper CL, Weidinger G, Riehle KJ, et al.: Distinct Wnt signaling pathways have opposing roles in appendage regeneration. Development 2007, 134:479–489.CrossRefPubMed

Dissanayake SK, Olkhanud PB, O’Connell MP, et al.: Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res 2008, 68:10205–10214.CrossRefPubMed

Chien AJ, Moore EC, Lonsdorf AS, et al.: Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 2009, 106:1193–1198.CrossRefPubMed

Rijsewijk F, Schuermann M, Wagenaar E, et al.: The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 1987, 50:649–657.CrossRefPubMed

Moon RT, Kohn AD, De Ferrari GV, Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004, 5:691–701.CrossRefPubMed

Chien AJ, Moon RT. WNTS and WNT receptors as therapeutic tools and targets in human disease processes. Front Biosci 2007, 12:448–457.CrossRefPubMed

Moon RT, Bowerman B, Boutros M, Perrimon N: The promise and perils of Wnt signaling through beta-catenin. Science 2002, 296:1644–1646.CrossRefPubMed

10.

Maretto S, Cordenonsi M, Dupont S, et al.: Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A 2003, 100:3299–3304.CrossRefPubMed

11.

Yost C, Torres M, Miller JR, et al.: The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996, 10:1443–1454.CrossRefPubMed

12.

van Meurs JB, Trikalinos TA, Ralston SH, et al.: Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA 2008, 299:1277–1290.CrossRefPubMed

13.

Mani A, Radhakrishnan J, Wang H, et al.: LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007, 315:1278–1282.CrossRefPubMed

14.

De Ferrari GV, Papassotiropoulos A, Biechele T, et al.: Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer’s disease. Proc Natl Acad Sci U S A 2007, 104:9434–9439.CrossRefPubMed

15.

White BD, Nathe RJ, Maris DO, et al.: Beta-catenin signaling increases in proliferating NG2+ progenitors and astrocytes during post-traumatic gliogenesis in the adult brain. Stem Cells 2010, 28:297–307.PubMed

16.

Stoick-Cooper CL, Moon RT, Weidinger G: Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine. Genes Dev 2007, 21:1292–1315.CrossRefPubMed

17.

Zhang Q, Major MB, Takanashi S, et al.: Small-molecule synergist of the Wnt/beta-catenin signaling pathway. Proc Natl Acad Sci U S A 2007, 104:7444–7448.CrossRefPubMed

18.

Teo JL, Ma H, Nguyen C, et al.: Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc Natl Acad Sci U S A 2005, 102:12171–12176.CrossRefPubMed

19.

••Huang SM, Mishina YM, Liu S, et al.: Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614–620. Tankyrase provides a novel means for small molecule–based inhibition of Wnt/β-catenin signaling, and the novel compound XAV939 identified in this study will serve as an important tool for studying Wnt in different model systems. CrossRefPubMed

20.

Gandhirajan RK, Staib PA, Minke K, et al.: Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 2010, 12:326–335.PubMed

21.

Fujii N, You L, Xu Z, et al.: An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 2007, 67:573–579.CrossRefPubMed

22.

••Chen B, Dodge ME, Tang W, et al.: Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009, 5:100–107. Using chemical genetic screening, these authors identified two classes of compounds that could inhibit Wnt signaling through either regulation of Wnt processing or regulation of AXIN stability. CrossRefPubMed

23.

Dorsky RI, Raible DW, Moon RT: Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. Genes Dev 2000, 14:158–162.PubMed

24.

Dorsky RI, Moon RT, Raible DW: Environmental signals and cell fate specification in premigratory neural crest. Bioessays 2000, 22:708–716.CrossRefPubMed

25.

Dorsky RI, Moon RT, Raible DW: Control of neural crest cell fate by the Wnt signalling pathway. Nature 1998, 396:370–373.CrossRefPubMed

26.

Fang D, Leishear K, Nguyen TK, et al.: Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells 2006, 24:1668–1677.CrossRefPubMed

27.

Thomas DM: Wnts, bone and cancer. J Pathol 2010, 220:1–4.CrossRefPubMed

28.

Delmas V, Beermann F, Martinozzi S, et al.: Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 2007, 21:2923–2935.CrossRefPubMed

29.

Widlund HR, Horstmann MA, Price ER, et al.: Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 2002, 158:1079–1087.CrossRefPubMed

30.

Maelandsmo GM, Holm R, Nesland JM, et al.: Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 2003, 9:3383–3388.PubMed

31.

Kageshita T, Hamby CV, Ishihara T, et al.: Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 2001, 145:210–216.CrossRefPubMed

32.

Bachmann IM, Straume O, Puntervoll HE, et al.: Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 2005, 11:8606–8614.CrossRefPubMed

33.

Tsao H, Bevona C, Goggins W, Quinn T: The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003, 139:282–288.CrossRefPubMed

34.

Bittner M, Meltzer P, Chen Y, et al.: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406:536–540.CrossRefPubMed

35.

Da Forno PD, Pringle JH, Hutchinson P, et al.: WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res 2008, 14:5825–5832.CrossRefPubMed

36.

Moon RT, Campbell RM, Christian JL, et al.: Xwnt-5A: a maternal Wnt that affects morphogenetic movements after overexpression in embryos of Xenopus laevis. Development 1993, 119:97–111.PubMed

37.

Ellison DW, Onilude OE, Lindsey JC, et al.: beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005, 23:7951–7957.CrossRefPubMed

38.

•Fattet S, Haberler C, Legoix P, et al.: Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009, 218:86–94. This study confirmed previous work showing that activating mutations of β-catenin (CTNNB1) can impressively predict improved patient prognosis, providing strong evidence that activation of Wnt signaling in medulloblastoma is not “oncogenic.” CrossRefPubMed

39.

Kool M, Koster J, Bunt J, et al.: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008, 3:e3088.CrossRefPubMed

40.

Horvath LG, Henshall SM, Lee CS, et al.: Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer 2005, 113:415–422.CrossRefPubMed

41.

Gamallo C, Palacios J, Moreno G, et al.: beta-Catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999, 155:527–536.PubMed

42.

Elzagheid A, Buhmeida A, Korkeila E, et al.: Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol 2008, 14:3866–3871.CrossRefPubMed

43.

••Morris JP, Cano DA, Sekine S, et al.: Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest 2010, 120:508–520. Using an established transgenic mouse model for pancreatic adenocarcinoma, these authors show that targeted activation of Wnt/β-catenin signaling can block the formation of pre-neoplastic lesions mediated by activation of Kras, which is a hallmark event in almost all pancreatic ductal adenocarcinoma. PubMed

44.

Heiser PW, Cano DA, Landsman L, et al.: Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology 2008, 135:1288–1300.CrossRefPubMed

Title: A Re-evaluation of the “Oncogenic” Nature of Wnt/β-catenin Signaling in Melanoma and Other Cancers
Authors: Olivia M. Lucero
David W. Dawson
Randall T. Moon
Andy J. Chien
Publication date: 01-09-2010
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 5/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-010-0114-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Indoor Tanning Use Among U.S. Youth—Can Skin Health Behaviors be Legislated?

Indoor Tanning and Substance-Related Disorder—Related Behaviors With Similar Treatment?

How Sunlight Causes Melanoma

Haploidentical Transplantation for Leukemia

Small Cell Lung Cancer: Past, Present, and Future

Molecular Testing in Lung Cancer: The Time Is Now

Keynote webinar | Spotlight on antibody–drug conjugates in cancer